Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) Non Operating Income (2016 - 2026)

United Therapeutics' Non Operating Income history spans 17 years, with the latest figure at -$85.2 million for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 27.43% to -$85.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$38.5 million, a 64.68% increase, with the full-year FY2025 number at $48.9 million, up 743.1% from a year prior.
  • Non Operating Income hit -$85.2 million in Q4 2025 for United Therapeutics, down from $6.1 million in the prior quarter.
  • Over the last five years, Non Operating Income for UTHR hit a ceiling of $102.8 million in Q4 2023 and a floor of -$117.4 million in Q4 2024.
  • Historically, Non Operating Income has averaged -$1.7 million across 5 years, with a median of -$950000.0 in 2022.
  • Biggest five-year swings in Non Operating Income: crashed 1796.3% in 2022 and later skyrocketed 2161.11% in 2025.
  • Tracing UTHR's Non Operating Income over 5 years: stood at -$33.0 million in 2021, then surged by 83.94% to -$5.3 million in 2022, then skyrocketed by 2039.62% to $102.8 million in 2023, then tumbled by 214.2% to -$117.4 million in 2024, then grew by 27.43% to -$85.2 million in 2025.
  • Business Quant data shows Non Operating Income for UTHR at -$85.2 million in Q4 2025, $6.1 million in Q3 2025, and -$100000.0 in Q2 2025.